The Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patient with Colorectal Cancer Has Completed the Enrollment of All Subjects

Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO

Simcere Releases 2021 Environmental, Social and Governance (ESG) Report

SIM0335, Simcere's Investigational Drug for Psoriasis Entered Phase II Clinical Trial and has completed the first patient enrollment

Simcere’s Covid-19 Prevention Pill Is First in China to Get Green Light to Start Clinical Trials

New Evidence of Sanbexin^® in AIS treatment Published During ESOC 2022

Simcere Completes Patient Enrollment for Phase 3 Registrational Study of Sanbexin Sublingual Tablet

New targets for AD, cancer and COVID19 therapy revealed at Simcere Innovation Forum 2021

Envafolimab and Trilaciclib Included in 4 Updated CSCO 2022 Guidelines

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day